Immunogenicity of induced pluripotent stem cells.

  title={Immunogenicity of induced pluripotent stem cells.},
  author={Keisuke Okita and Naoki Nagata and Shinya Yamanaka},
  journal={Circulation research},
  volume={109 7},
### Immunogenicity of Induced Pluripotent Stem Cells Zhao et al Nature . 2011. doi:10.1038/nature10135 A new study shows the immunogenicity of induced pluripotent stem cells by the direct transplantation of undifferentiated cells into syngenic mice. The reprogramming of somatic cells into pluripotent stem cells has been reported after introducing a combination of several defined factors, such as OCT3/4, SOX2, KLF4, and c-MYC, into the cells.1 These artificially established cells are termed… 

Figures from this paper

Induced pluripotent stem cells: Mechanisms, achievements and perspectives in farm animals.

An increased understanding of the fundamental mechanisms underlying pluripotency and refining the methodology of iPS cell generation will have a profound impact on future development and application in regenerative medicine and reproductive biotechnology of farm animals.

The immunogenicity of cells derived from induced pluripotent stem cells

  • Xuemei Fu
  • Biology
    Cellular and Molecular Immunology
  • 2014
A recent breakthrough in the technology of induced pluripotent stem cells (iPSCs) by nuclear reprogramming of patient-specific somatic cells with defined factors could become a renewable source of autologous cells for cell therapy.

Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells

Limited immunogenicity of transplanted cells differentiated from iPSCs and ES cells is suggested, suggesting limited immune responses in transplant recipients even when iPSC-derived differentiated cells are transplanted.

Naive-like Conversion Overcomes the Limited Differentiation Capacity of Induced Pluripotent Stem Cells*

Improving their level of pluripotency alleviated the limited capacity of induced pluripotent stem cells by converting them into the so-called “naive” state, suggesting that the naive-like conversion of iPS cells might endow them with a higher differentiation capacity.

Induced pluripotent stem cells: progress and future perspectives in the stem cell world.

Pluripotent stem cells (PSCs) have the potential to differentiate into many cell types and therefore can be a valuable source for cell therapy. Embryonic stem cells (ESCs), which are derived from the

Pluripotent Stem Cell Banks

The emerging demands of stem cell research and applications require the establishment and cooperation of centralized banks at a translational and even global scale to ensure the availability of high-quality hPSC using standardized state-of-the-art methods and strategies to deal with a heterogeneous regulatory, ethical and legal landscape.

Induced Pluripotent Stem Cells in Cardiovascular Medicine

This paper summarizes the progress of iPS cell technology in cardiovascular research and indicates that cardiomyocyte transplantation may be a reality in the future.

Human-Induced Pluripotent Stem Cells: In Quest of Clinical Applications

Methods to develop induced pluripotent stem cells, current strategies for direct reprogramming, and main applications of iPS cells as human disease model, focusing on human cardiovascular diseases are overviewed to be a potential information resource for biomedical scientists and clinicians who exploit or intend to exploit iPS cell technology in a range of applications.

Low immunogenicity of mouse induced pluripotent stem cell-derived neural stem/progenitor cells

The immunogenicity and post-transplantation immunological dynamics of iPSC-NSPCs resemble those of fetus-N SPCs.



Immunogenicity of induced pluripotent stem cells

Findings indicate that, in contrast to derivatives of ESCs, abnormal gene expression in some cells differentiated from iPSCs can induce T-cell-dependent immune response in syngeneic recipients.

Therapeutic potential of appropriately evaluated safe-induced pluripotent stem cells for spinal cord injury

The directed neural differentiation of murine iPS cells is shown and it is suggested that pre-evaluated safe iPS clone-derived neural stem/progenitor cells may be a promising cell source for transplantation therapy for SCI.

Natural immunity to pluripotency antigen OCT4 in humans

It is shown that OCT4-specific T cells can be readily detected in freshly isolated T cells from most (>80%) healthy donors, and natural immunity to this antigen may allow immune-based targeting of pluripotency-related pathways for prevention of cancers, including those in the setting of ES/IPS-based therapies.

Marked differences in differentiation propensity among human embryonic stem cell lines

Non-trivial differences in developmental potential among hES cell lines point to the importance of screening and deriving lines for lineage-specific differentiation.

Identification of CT46/HORMAD1, an immunogenic cancer/testis antigen encoding a putative meiosis-related protein.

One of these new CT and CT-like genes, CT46/HORMAD1, is expressed strongly in testis and weakly in placenta; the highest level of expression in other tissues is <1% of testicular expression.

Treatment of Sickle Cell Anemia Mouse Model with iPS Cells Generated from Autologous Skin

It is shown that mice can be rescued after transplantation with hematopoietic progenitors obtained in vitro from autologous iPS cells, providing proof of principle for using transcription factor–induced reprogramming combined with gene and cell therapy for disease treatment in mice.

Induction of pluripotent stem

  • cells